

**EDUCATION**

**University of Puerto Rico**

**School of Medicine**

**University District Hospital**

Hematology/Medical Oncology Fellowship

Puerto Rico Medical Center

San Juan, PR 00921

(07/2012 – 06/30/2015)

**Hospital de la Concepción**

**Ponce School of Medicine Associate Program**

Internal Medicine Residency

Chief Resident as PGY-3

San Germán, Puerto Rico

(07/2009 - 06/2012)

**Sound Shore Medical Center**

**New York Medical College**

Fifth Pathway Program Certificate

New Rochelle, N.Y.

(07/2007 - 06/2008)

**Manatí Medical Center**

Off Campus 4th year COOP Program

Manatí, P.R.

(01/2006 - 12/2006)

**Universidad Autónoma de Guadalajara**

**School of Medicine**

Medical Doctor Graduate

Guadalajara, Jalisco, Mexico

(07/2002-12/2006)

**University of Puerto Rico**

Sciences and Mechanical Arts Faculty

Biology Department

Bachelor in Science of Biology

Mayagüez, PR

(08/1998-06/2002)



**WORK  
EXPERIENCE**

**New Horizons Hematology & Oncology Group P.S.C.**

550 Calle Sergio Cuevas Bustamante  
Hospital del Maestro Suite 2002  
San Juan, PR 00918  
President  
Private Practice in Hematology/Medical Oncology  
(06/2016 – Present)

**Fundacion de Investigacion**

998 Luis Muñoz Rivera Ave.  
San Juan, Puerto Rico 00927  
Principal Investigator/Sub Investigator  
(09/2015- Present)

**University of Puerto Rico  
School of Medicine**

Paseo Dr. Jose Celso Barbosa  
Puerto Rico Medical Center  
San Juan, PR 00921  
Assistant Professor  
(07/2015 – Present)

**Hematology/Medical Oncology Training Program**

**University of Puerto Rico**

**School of Medicine**

**University District Hospital**

Puerto Rico Medical Center  
San Juan, PR 00921  
Medical Faculty  
Attending Physician  
(07/2015 – Present)

**Centro Cardiovascular de Puerto Rico y del Caribe**

Puerto Rico Medical Center  
San Juan, PR 00921  
Medical Faculty  
Hematology/Medical Oncology Consultant  
(07/2015 – Present)

**Hospital del Maestro**

550 Calle Sergio Cuevas Bustamante  
San Juan, PR 00918  
Medical Faculty  
Hematology/Medical Oncology Consultant  
(07/2015 – Present)

**RESEARCH  
EXPERIENCE AS  
PRINCIPAL  
INVESTIGATOR**

***Luitpold Pharmaceuticals (1VIT14039)-***

IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose injection).

***GlaxoSmithKline Pharmaceuticals (TRC112121)-***

A randomized, double-blind, placebo-controlled Phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndromes (MDS).

**RESEARCH  
EXPERIENCE AS  
SUB-INVESTIGATOR**

***Merck (MK-7902-012)***

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

***Merck (MK-7339-007)***

A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

***Regeneron (R2810-ONC-1806)***

Cemiplimab Survivorship Epidemiology (CASE) Study

***Bristol (CA-209-7A8)***

Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer  $\geq$  2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole

***Bristol (CA-209-9DW)***

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

***Bristol (CA-209-9DX)***

A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

***Eli Lilly (I3Y-MC-JPCU)***

A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Metastatic Breast Cancer with Visceral Metastases

***Eli Lilly (I4T-MC-JVDE)***

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

***Bristol (CA-224-060)***

A Randomized, Open-label, Phase II Clinical Trial of of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

***Bristol (CA-209-9x8)***

An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer

***Macrogenics (CP-MGAH22-04)***

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

**Bristol (CA-209-9GW)**

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors

**Bristol (CA-209-040)**

A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy

**Merck Pharmaceuticals (MK3474-045)**- A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer.

**Merck Pharmaceuticals (MK3475-040)**- A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer.

**Merck Pharmaceuticals (MK3475-062)**- A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

**Merck Pharmaceuticals (V212-011)**- A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy.

**Celgene Corporation (CC4047-MM-0114)**- A Phase 2, multicenter, single arm, open label study of pomalidomide in combination with low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma following lenalidomide plus dexamethasone in the second line setting.

**Celgene Corporation**- Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Disease (AML) Registry.

**Amgen Inc. (200707872)**- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multicycle Chemotherapy.

**Pronai (PNT2258-03-DLBCL)Wolverine**- A Phase II Study PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

**Bristol (CA130-001-009)** - A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small cell Lung Cancer.

**Astellas (9785-CL-3021)** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma.

**Sillajen (JX594-HEP024)**-A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy.

## ASSOCIATIONS

American College of Physicians  
North American Student Association  
American Society of Hematology  
American Society of Clinical Oncology  
Asociacion de Hematologia y Oncologia Medica de Puerto Rico (Treasurer 10/2016 – Present)

## HONORS / AWARDS

### **Well Rounded Medical Student Award**

North American Student Association  
(2004)

### **Medical School Class Ranking Award**

Top three GPA's  
(2006)

### **Dean's list**

(2003-2006)

**Second Prize Winner: Clinical Research Podium  
Presentation Ponce School of Medicine 6<sup>th</sup> Annual  
Scientific Conference.**

Title: *Adequate Vancomycin Dosing Regimen for  
Inpatients on High Flux Hemodialysis*

Authors: Yazmín Soto-Guerrero (Presenter), Ricardo  
Hernández-Castillo, Edgardo L. Santiago-Guzmán,  
Rebeca Jové, Efraín Flores, Roberto Lebrón, Norman  
Ramírez Lluch Ponce, P.R. (04/2010)

**Harvey Ramírez Bates Memorial Award of  
Excellence**

PGY-1 Internal Medicine Resident of the year  
Hospital de la Concepción San Germán, P.R. (06/2010)

**PGY-2, PGY-3 In-Training Exam**

Top score - Internal Medicine Residency  
Hospital de la Concepción  
San Germán, P.R. (10/2010, 10/2011)

**Clinical Research Podium Presentation: American  
College of Physicians Puerto Rico National Scientific  
Meeting.**

Title: *Adequate Vancomycin Dosing Regimen for  
Inpatients on High Flux Hemodialysis*

Authors: Yazmín Soto-Guerrero (Presenter), Ricardo  
Hernández-Castillo, Edgardo L. Santiago-Guzmán,  
Rebeca Jové, Efraín Flores, Roberto Lebrón, Norman  
Ramírez Lluch. San Juan, P.R. (02/2011)

**Harvey Ramírez Bates Memorial Award of  
Excellence**

PGY-2 Internal Medicine Resident of the year  
Hospital de la Concepción  
San Germán, P.R. (06/2011)

**Harvey Ramírez Bates Memorial Award of  
Excellence**

PGY-3 Internal Medicine Resident of the year  
Hospital de la Concepción San Germán, P.R.  
(06/2012)

**CERTIFICATIONS**

USMLE Step 1, 2 and 3  
Diplomate of the American Board of Internal  
Medicine  
Diplomate of the American Board of Hematology  
Diplomate of the American Board of Clinical  
Oncology  
Terminal Illness Assessment Certificate  
HIPAA Certificate  
Child Abuse Identification and Reporting Certificate  
Basic Life Support Certificate  
Advanced Cardiac Life Support Certificate  
Infection Control Certificate